about
Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporterDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTFilming biomolecular processes by high-speed atomic force microscopyEffects of Huanglian-Jie-Du-Tang and its modified formula on the modulation of amyloid-β precursor protein processing in Alzheimer's disease modelsPeptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's diseaseImplication of Complement System and its Regulators in Alzheimer’s DiseaseDiscovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein.Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.Assessment of neuroprotection in the retina with DARC.Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease.The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent mannerA hyperpolarized choline molecular probe for monitoring acetylcholine synthesis.Amyloid-beta immunotherapy for Alzheimer's diseasePotential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trialsNeuroprotective effects of sulforaphane on cholinergic neurons in mice with Alzheimer's disease-like lesions.Metal chaperones: a holistic approach to the treatment of Alzheimer's diseaseEpigenetic regulation of fatty acid amide hydrolase in Alzheimer diseasePd-catalyzed amination as an alternative to nucleophilic aromatic substitution for the synthesis of N-alkyltacrines and analogues.S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro.The proton-pump inhibitor lansoprazole enhances amyloid beta production.The Structured Interview & Scoring Tool-Massachusetts Alzheimer's Disease Research Center (SIST-M): development, reliability, and cross-sectional validation of a brief structured clinical dementia rating interview.Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.Neuronal death in Alzheimer's disease and therapeutic opportunities.Dietary fat types and 4-year cognitive change in community-dwelling older women.Neurological disorders and therapeutics targeted to surmount the blood-brain barrierNMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Cannabinoid CB2 receptors in human brain inflammation.Therapeutic options in Alzheimer's disease.100 years and counting: prospects for defeating Alzheimer's diseaseTargeting acetylcholinesterase to treat neurodegeneration.Vascular disease and dementias: paradigm shifts to drive research in new directionsComparative Study of White and Steamed Black Panax ginseng, P. quinquefolium, and P. notoginseng on Cholinesterase Inhibitory and Antioxidative Activity.Looking for novel ways to treat the hallmarks of Alzheimer's disease.Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment.Medical management of frontotemporal dementia.Parishin from Gastrodia elata Extends the Lifespan of Yeast via Regulation of Sir2/Uth1/TOR Signaling PathwayInflammation and aging: can endocannabinoids help?Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients.
P2860
Q24650088-D3C7AB0A-2D28-435E-B0C8-4E84EA7B65F9Q26749755-6FDC5D5F-27F8-4400-B793-F4BB52AFEEA1Q27021717-5C8D9098-C75D-44DC-8F7A-F8859FEBAFB3Q28541573-2E00038F-4C60-45BF-9125-BD0B865904A2Q28546835-03BEFC70-A2DD-4982-85AE-6102E79F6C75Q28972502-9DBD5B8D-CB8B-435E-97D5-9B78BE72F28CQ30474039-2DB3B1C9-0C0F-4A4F-9E3F-D9C62378150FQ30481489-D11E5617-22ED-4710-8E11-49C518ACAE48Q30512265-92828A31-0FC7-4B2A-9FE0-745F4457EE7EQ33291589-9EAA36CB-9BC1-431B-B9C9-CBC0F70EE067Q33377667-EE19DCD1-2247-4A5E-9C7C-175CEE511DB1Q33460503-62FC9C70-933D-4AAB-B7CC-805A4ECFF2C7Q33927277-A2008E26-EB4D-4EC6-9352-6FDF7F4ACD41Q33941482-5177DF7D-7B14-43E0-A39C-CDC28CA9B8BCQ33954737-864F1951-5C05-4465-8020-5DBF0CF60DBAQ34014237-C15C60D8-DDC9-40E3-8C72-6E5E42465EFBQ34158616-A123FD77-E257-486F-869D-6E140C517F2CQ34260002-7D802CFD-F27D-450B-AF71-2BDD5A5086F9Q34312272-7E808540-19A1-40AA-9BC2-A401A10551D7Q34535821-A7EA4B45-3991-4C60-9336-501C427C08B5Q34561747-94EA92EB-FFD3-4339-9EBE-001A9FED7399Q34631939-AD110863-5C9F-4375-9770-EFA1C847E840Q34681067-F0F94CB3-D52B-4507-8E62-E13DC26CE319Q35313148-6188924B-4D20-4BD9-BD9D-E9C9F6C7D851Q35889067-7AF801FC-9301-4FD6-BD63-D1D354E6B87DQ36117079-2ADBB78D-D860-4FF7-AE28-7C849BE431E2Q36119574-AAD662D1-EF9B-47D3-8732-E480F9C20DF6Q36310524-6805F290-C877-4AD7-9A45-D733617A8575Q36416377-31ED8C1E-A1F9-4F71-92BE-18AEABCBD0D4Q36511328-A7581E3C-C8B9-4919-BB70-6B54AA245A3AQ36643419-686B3C74-9F7F-4421-8E33-DE9678C90095Q36709537-07094FF9-4D21-4D3C-ABEF-E76B53887DC8Q36808201-0D6220E4-C23A-4DA0-8D5E-629E4D2A7341Q36861025-64E76CCB-C266-48DA-8C93-861132E92783Q36904846-E030F8AC-1E53-40A4-93FC-2EAE3F00B2F0Q36969034-5E16FD7D-C969-489E-8618-C95ADC272C1AQ37048086-57264F4A-B4F7-4CB6-8720-D4F375915A95Q37081076-5AC00675-FF98-4E5D-BA68-993AFC413BBBQ37133525-479F82E1-5B7B-4708-87E2-6FC6D23523FFQ37237443-C04EC62D-615D-4243-9486-52CAC876328D
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Current pharmacotherapy for Alzheimer's disease.
@ast
Current pharmacotherapy for Alzheimer's disease.
@en
Current pharmacotherapy for Alzheimer's disease.
@nl
type
label
Current pharmacotherapy for Alzheimer's disease.
@ast
Current pharmacotherapy for Alzheimer's disease.
@en
Current pharmacotherapy for Alzheimer's disease.
@nl
prefLabel
Current pharmacotherapy for Alzheimer's disease.
@ast
Current pharmacotherapy for Alzheimer's disease.
@en
Current pharmacotherapy for Alzheimer's disease.
@nl
P2093
P1476
Current pharmacotherapy for Alzheimer's disease.
@en
P2093
P304
P356
10.1146/ANNUREV.MED.57.121304.131442
P577
2006-01-01T00:00:00Z